GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company’s cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on October 16, 2026, to shareholders of record at the close of business on September 25, 2026.
Medtronic announces cash dividend for second quarter of fiscal year 2027
1 min read Premium comments
Medtronic plcQ2FY2027fiscal yearsecond quartercash dividend
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Justin Paquette
Public Relations
+1-612-271-7935
Ingrid Goldberg
Investor Relations
+1-763-505-2696
SOURCE Medtronic plc
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Medtronic's board approved a $0.72 cash dividend for Q2 FY2027, signaling strong financial health and commitment to shareholder returns. This consistent dividend growth, marking 49 consecutive years and maintaining its S&P 500 Dividend Aristocrat status, reinforces investor confidence. Such financial stability supports strategic investments and market leadership in healthcare technology.
- The dividend aligns with Medtronic's strategy to reward shareholders and attract capital, reflecting robust financial performance.
- Consistent dividend increases enhance Medtronic's market reputation, potentially influencing competitive positioning and long-term valuation.
PhD Lens: Clinical and outcomes impact
This article announces Medtronic's cash dividend for the second quarter of fiscal year 2027, set at $0.72 per ordinary share. It is a financial news release and does not contain information regarding specific mechanisms of action, materials science, clinical evidence, patient outcomes, or safety profiles of Medtronic's technologies or therapies.
- The article does not provide details on biomedical research, device efficacy, or clinical trial results.
- Information on specific health conditions treated or technology types is mentioned generally, without scientific depth.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.